CRISPR gene editing and cell/gene therapies alongside the broader oncology and rare-disease drug-discovery pipeline. Spans pure-play editors (Vertex/CRISPR's Casgevy on-market; Beam and Intellia in the clinic) through big-pharma programs bringing targeted therapeutics to patients.
Browse all macro trends · Product categories · Industries · Companies